Discovery of Novel c‑MET Inhibitors for Hepatocellular Carcinoma Using an Integrated Virtual Screening Approach

利用整合虚拟筛选方法发现用于治疗肝细胞癌的新型c-MET抑制剂

阅读:1

Abstract

Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related mortality worldwide, with the efficacy of current targeted therapies limited by drug resistance and adverse effects. The receptor tyrosine kinase c-MET has been identified as a promising target for HCC therapy due to its involvement in tumor progression, metastasis, and poor prognosis. However, no c-MET inhibitors have been approved for HCC treatment. This study integrates a multistep virtual screening workflow, incorporating molecular docking, machine learning-based predictions, and molecular dynamics simulations, to identify novel c-MET inhibitors with unique structural frameworks. Among several promising candidates, compound 10 exhibited potent c-MET inhibition and selective antiproliferative effects against the HCC cell line Hep3B. Further molecular dynamics simulations confirmed the binding stability of compound 10 with c-MET, highlighting key interactions that contribute to its inhibitory activity. These findings provide valuable insights into the development of c-MET inhibitors with potential therapeutic applications for HCC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。